Pharmafile Logo
  • - PMLiVE
  • - PMLiVE
  • Diversity, Equity and Inclusion
  • Communiqué 53 Cover Image

    • Chiesi

    - PMLiVE

    AstraZeneca shares late-stage results for Airsupra in mild asthma patients

    More than ten million asthma exacerbations occur in the US every year

    - PMLiVE

    AstraZeneca’s triple-combination COPD therapy shows promise in uncontrolled asthma

    Up to 262 million people worldwide are affected by the chronic respiratory disease

    - PMLiVE

    Chiesi report highlights incorrect inhaler use among UK asthma patients

    The long-term lung condition affects around 7.2 million people in the UK

    - PMLiVE

    Gilead and LEO enter inflammatory disease partnership worth up to $1.7bn

    Targeting STAT6 has shown potential in treating a broad population of inflammatory disease patients

    - PMLiVE

    UK researchers uncover first new asthma and COPD attack treatment in 50 years

    The phase 2 study showed that benralizumab could be re-purposed for use in emergency settings

    - PMLiVE

    AstraZeneca/Avillion share positive phase 3 results for asthma rescue treatment Airsupra

    The chronic respiratory disease is estimated to affect up to 262 million people globally

    - PMLiVE

    Chiesi Group invests €400m to establish biotech centre of excellence in Italy

    The facility is dedicated to developing and producing monoclonal antibodies, enzymes and other proteins

    - PMLiVE

    Chiesi’s rare disorder therapies approved by SMC for Fabry disease and epidermolysis bullosa

    Rare diseases currently affect around 436,000 people living in Scotland

    - PMLiVE

    GSK to expand respiratory pipeline with $1.4bn Aiolos Bio acquisition

    The deal includes a monoclonal antibody ready to enter phase 2 development for asthma

    - PMLiVE

    NICE recommends Chiesi’s alpha-mannosidosis enzyme replacement therapy

    Alpha-mannosidosis, an extremely rare inherited condition characterised by a broad range of impairments, affects approximately 25 people in England

    - PMLiVE

    NICE recommends Chiesi’s Elfabrio for adults with Fabry disease

    Affecting approximately 1,150 people in England, Fabry disease is a rare genetic disease that can lead to progressive damage to vital organs

    - PMLiVE

    AstraZeneca’s mild combination asthma reliever approved in UK

    Over two and a half million adults with mild cases of asthma could be eligible for the treatment

    Subscribe to our email news alerts

    Latest content

    Latest intelligence

    Quick links